Research Paper Volume 12, Issue 17 pp 17694—17712
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
Figure 3. Doc treatment increased ARv7 in CRPC and DocRPC cells. (A, B) ARv7 expression (left panel: immunoblot for protein level; right panel: real-time PCR for mRNA level) is higher in DocR1_ and DocR2_CWR22Rv1 compared to DocS1_ and DocS2_CWR22Rv1 cells. (C–F) Increasing ARv7 expressions at protein levels and mRNA levels upon transient Doc treatment in Doc naïve parental CWR22Rv1 (C, D) and VCaP (E, F) cells. After treating parental CWR22Rv1 or VCaP cells with DMSO or Doc, then ARv7 mRNA (C, E) and ARv7 protein (D, F) were assayed. Results are mean ± SD compared to controls, *p<0.05; **p<0.01; ***p<0.001.